CRBU RSI Chart
Last 7 days
-1.9%
Last 30 days
-10.7%
Last 90 days
-48.2%
Trailing 12 Months
-18.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 33.2M | 0 | 0 | 0 |
2023 | 14.7M | 0 | 34.2M | 34.4M |
2022 | 10.7M | 13.4M | 12.7M | 13.9M |
2021 | 12.2M | 5.2M | 8.0M | 9.6M |
2020 | 7.4M | 9.1M | 10.7M | 12.4M |
2019 | 0 | 0 | 0 | 5.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 20, 2024 | khan ruhi ahmad | acquired | - | - | 33,000 | chief business officer |
Feb 20, 2024 | o'byrne jason | acquired | - | - | 33,000 | chief financial officer |
Feb 20, 2024 | kanner steven | acquired | - | - | 33,000 | chief scientific officer |
Feb 20, 2024 | haurwitz rachel e. | acquired | - | - | 118,700 | president and ceo |
Feb 20, 2024 | mcclung barbara g | acquired | - | - | 33,000 | chief legal officer |
Feb 06, 2024 | kanner steven | acquired | 82,252 | 2.69 | 30,577 | chief scientific officer |
Jun 08, 2023 | haurwitz rachel e. | acquired | 29,600 | 2.96 | 10,000 | president and ceo |
Mar 20, 2023 | haurwitz rachel e. | acquired | 29,600 | 2.96 | 10,000 | president and ceo |
Jan 19, 2023 | rizvi syed ali-aamir | sold | -35,506 | 6.31 | -5,627 | chief medical officer |
Dec 02, 2022 | kanner steven | acquired | 57,568 | 2.69 | 21,401 | chief scientific officer |
Which funds bought or sold CRBU recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Curi RMB Capital, LLC | added | 22.15 | 41,866 | 479,351 | 0.01% |
May 15, 2024 | Woodline Partners LP | reduced | -79.2 | -5,316,440 | 1,219,600 | 0.01% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 2,708,340 | 2,708,340 | -% |
May 15, 2024 | Corton Capital Inc. | added | 7.1 | -2,870 | 70,182 | 0.03% |
May 15, 2024 | SILVERARC CAPITAL MANAGEMENT, LLC | sold off | -100 | -5,161,690 | - | -% |
May 15, 2024 | Rokos Capital Management LLP | unchanged | - | -500,174 | 4,304,030 | 0.02% |
May 15, 2024 | Paradigm Biocapital Advisors LP | reduced | -25.69 | -5,586,400 | 11,167,300 | 0.39% |
May 15, 2024 | Man Group plc | sold off | -100 | -126,679 | - | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | reduced | -24.52 | -377,320 | 791,216 | -% |
May 15, 2024 | Voya Investment Management LLC | reduced | -17.23 | -48,232 | 139,047 | -% |
Unveiling Caribou Biosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Caribou Biosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
Caribou Biosciences, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | -31.7% | 2,429,000 | 3,558,000 | 23,662,000 | 3,502,000 | 3,692,000 | 3,303,000 | 4,192,000 | 2,664,000 | 2,559,000 | 3,977,000 | 1,476,000 | 1,586,000 | 984,000 | 1,198,000 | 8,478,000 | 1,701,000 | - |
Operating Expenses | 18.1% | 48,431,000 | 41,000,000 | 38,295,000 | 34,618,000 | 34,270,000 | 29,840,000 | 32,623,000 | 23,517,000 | 22,964,000 | 22,593,000 | 17,440,000 | 14,761,000 | 16,195,000 | 9,427,000 | 10,733,000 | 12,130,000 | - |
S&GA Expenses | -100.0% | - | 9,721,000 | 9,711,000 | 8,909,000 | 8,534,000 | 9,849,000 | 10,044,000 | 9,593,000 | 7,853,000 | 6,760,000 | 5,113,000 | 4,596,000 | 4,171,000 | 3,247,000 | 3,153,000 | 3,489,000 | - |
R&D Expenses | 8.0% | 33,788,000 | 31,279,000 | 28,584,000 | 25,709,000 | 25,736,000 | 19,991,000 | 22,579,000 | 13,924,000 | 15,111,000 | 15,833,000 | 12,327,000 | 10,165,000 | 12,024,000 | 6,180,000 | 7,580,000 | 8,641,000 | - |
EBITDA Margin | -3.7% | -2.96 | -2.86 | -2.81 | -6.63 | -7.06 | -5.13 | -4.88 | -6.14 | -6.84 | -7.80 | -9.49 | -3.05 | -2.85 | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | 1,000 | - | 2,000 | 4,000 | 6,000 | 6,000 | 5,000 | - | - |
Income Taxes | -100.0% | - | 23,000 | - | - | 70,000 | - | - | - | 315,500 | - | - | - | -354,000 | -213,000 | -50,000 | -1,202,000 | - |
Earnings Before Taxes | - | - | - | - | - | -45,908,000 | - | - | - | -18,158,000 | -20,974,000 | -14,311,000 | -13,159,000 | -15,057,000 | -8,146,000 | -1,922,000 | -11,002,000 | - |
EBT Margin | -3.8% | -3.07 | -2.96 | -2.91 | -6.76 | -7.17 | -5.24 | -4.97 | -6.24 | -6.94 | -7.91 | -9.66 | -3.13 | -2.92 | - | - | - | - |
Net Income | -19.4% | -41,200,000 | -34,505,000 | -10,002,000 | -28,044,000 | -26,989,000 | -26,647,000 | -26,697,000 | -19,088,000 | -18,479,000 | -20,974,000 | -14,311,000 | -13,159,000 | -14,703,000 | -7,933,000 | -1,872,000 | -9,800,000 | - |
Net Income Margin | -17.2% | -3.48 | -2.97 | -2.77 | -7.38 | -7.18 | -7.15 | -6.36 | -6.82 | -6.97 | -7.87 | -9.55 | -3.08 | -2.78 | - | - | - | - |
Free Cashflow | -63.3% | -38,651,000 | -23,668,000 | -33,528,000 | -29,931,000 | -26,801,000 | -23,730,000 | -24,493,000 | -22,396,000 | -22,074,000 | -15,897,000 | -16,960,000 | 20,291,000 | -8,103,000 | - | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -5.9% | 407 | 432 | 458 | 350 | 347 | 374 | 399 | 421 | 446 | 442 | 462 | 158 | 36.00 |
Current Assets | -10.1% | 305 | 339 | 351 | 269 | 239 | 260 | 307 | 353 | 368 | 391 | 449 | 143 | 24.00 |
Cash Equivalents | -3.4% | 49.00 | 51.00 | 104 | 66.00 | 53.00 | 58.00 | 82.00 | 112 | 148 | 240 | 435 | 130 | 16.00 |
Net PPE | 4.9% | 19.00 | 18.00 | 17.00 | 15.00 | 13.00 | 11.00 | 9.00 | 8.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 |
Liabilities | -0.4% | 64.00 | 64.00 | 59.00 | 80.00 | 69.00 | 73.00 | 75.00 | 73.00 | 74.00 | 55.00 | 58.00 | 56.00 | 18.00 |
Current Liabilities | 2.5% | 29.00 | 28.00 | 25.00 | 34.00 | 27.00 | 28.00 | 29.00 | 29.00 | 27.00 | 26.00 | 26.00 | 26.00 | 12.00 |
Shareholder's Equity | -6.8% | 343 | 368 | 398 | 269 | 278 | 301 | 324 | 348 | 372 | 388 | 404 | - | - |
Retained Earnings | -13.8% | -340 | -299 | -264 | -254 | -225 | -197 | -170 | -143 | -116 | -97.79 | -79.30 | -58.34 | -30.87 |
Additional Paid-In Capital | 2.5% | 684 | 668 | 664 | 525 | 504 | 500 | 496 | 493 | 490 | 486 | 484 | 11.00 | 7.00 |
Shares Outstanding | 2.1% | 90.00 | 88.00 | 88.00 | 66.00 | 61.00 | 61.00 | 61.00 | 61.00 | 61.00 | 60.00 | 46.00 | 10.00 | - |
Float | - | - | - | - | 263 | - | - | - | 308 | - | - | - | 538 | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | -73.9% | -37,203 | -21,391 | -28,776 | -15,224 | -27,900 | -25,044 | -22,376 | -21,873 | -21,673 | -21,389 | -14,967 | -16,476 | 20,313 | -8,076 | -8,691 | - | - |
Share Based Compensation | 12.1% | 3,988 | 3,556 | 3,478 | 3,585 | 3,131 | 3,101 | 2,673 | 2,918 | 3,024 | 1,578 | 935 | 593 | 343 | 231 | 248 | - | - |
Cashflow From Investing | 172.9% | 22,956 | -31,474 | -68,476 | 11,064 | 20,703 | 1,170 | -8,339 | -13,973 | -72,107 | -173,961 | -1,930 | -484 | -22.00 | -600 | -4.00 | - | - |
Cashflow From Financing | 29134.9% | 12,485 | -43.00 | 135,128 | 17,571 | 1,642 | 127 | 654 | 362 | 990 | 460 | 322,683 | 606 | 109,680 | 82.00 | 112 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 2,429 | $ 3,502 |
Operating expenses: | ||
Research and development | 33,788 | 25,709 |
General and administrative | 14,643 | 8,909 |
Total operating expenses | 48,431 | 34,618 |
Loss from operations | (46,002) | (31,116) |
Other income (expense): | ||
Change in fair value of equity securities | 0 | (15) |
Change in fair value of MSKCC success payments liability | 303 | 255 |
Other income, net | 4,465 | 2,832 |
Total other income | 4,768 | 3,072 |
Net loss | (41,234) | (28,044) |
Other comprehensive income (loss): | ||
Net unrealized (loss) gain on available-for-sale marketable securities, net of tax | (352) | 788 |
Net comprehensive loss | $ (41,586) | $ (27,256) |
Net loss per share, basic (in dollars per share) | $ (0.46) | $ (0.46) |
Net loss per share, diluted (in dollars per share) | $ (0.46) | $ (0.46) |
Weighted-average common shares outstanding, basic (in shares) | 89,302,937 | 61,186,514 |
Weighted-average common shares outstanding, diluted (in shares) | 89,302,937 | 61,186,514 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 49,400 | $ 51,162 |
Marketable securities, short-term | 244,588 | 277,665 |
Accounts receivable | 917 | 148 |
Contract assets | 971 | 1,425 |
Other receivables | 1,725 | 2,286 |
Prepaid expenses and other current assets | 6,913 | 6,155 |
Total current assets | 304,514 | 338,841 |
NON-CURRENT ASSETS | ||
Investments in equity securities | 7,753 | 7,753 |
Marketable securities, long-term | 51,938 | 43,577 |
Property and equipment, net | 19,167 | 18,270 |
Operating lease, right of use assets | 21,659 | 22,182 |
Other assets | 1,794 | 1,586 |
TOTAL ASSETS | 406,825 | 432,209 |
CURRENT LIABILITIES | ||
Accounts payable | 5,940 | 3,120 |
Accrued expenses and other current liabilities | 18,990 | 21,135 |
Operating lease liabilities, current | 1,264 | 1,200 |
Deferred revenue ($2,487 and $2,487 from related party, respectively) | 2,827 | 2,847 |
Total current liabilities | 29,021 | 28,302 |
LONG-TERM LIABILITIES | ||
Deferred revenue, net of current portion ($3,108 and $3,730 from related party, respectively) | 5,428 | 6,102 |
MSKCC success payments liability | 2,636 | 2,939 |
Operating lease liabilities, non-current | 25,895 | 25,908 |
Deferred tax liabilities | 556 | 557 |
Total liabilities | 63,536 | 63,808 |
COMMITMENTS AND CONTINGENCIES (Note 9) | ||
STOCKHOLDERS’ EQUITY | ||
Common stock, par value $0.0001 per share, 300,000,000 shares authorized at March 31, 2024, and December 31, 2023, respectively; 90,314,501 and $88,448,948 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively | 9 | 8 |
Additional paid-in-capital | 684,121 | 667,648 |
Accumulated other comprehensive (loss) income | (322) | 30 |
Accumulated deficit | (340,519) | (299,285) |
Total stockholders’ equity | 343,289 | 368,401 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 406,825 | $ 432,209 |